Denizen Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-07-2024
- Paid Up Capital ₹ 2.48 M
as on 16-07-2024
- Company Age 31 Year, 13 Days
- Last Filing with ROC 31 Mar 2023
- Revenue -27.77%
(FY 2023)
- Profit -77.19%
(FY 2023)
- Ebitda -17.74%
(FY 2023)
- Net Worth 1.67%
(FY 2023)
- Total Assets 22.26%
(FY 2023)
About Denizen Pharmaceuticals India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.48 M, as per Ministry of Corporate Affairs (MCA) records.
Anuj Gupta, Praveen Gupta, and Nikunj Gupta serve as directors at the Company.
- CIN/LLPIN
U74899DL1993PTC056429
- Company No.
056429
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Dec 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Denizen Pharmaceuticals India Private Limited offer?
Denizen Pharmaceuticals India Private Limited offers a wide range of products and services, including Common Disease Medicines, Psoriasis Ointment, Digestive System Drugs & Medicines, Anti Ulcer Drugs, Cardiovascular Drugs & Medication, Diabetes Medicine, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antifungal Cream, Ointment & Powder, Pharma Ingredients & Raw Materials.
Who are the key members and board of directors at Denizen Pharmaceuticals India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anuj Gupta  | Director | 04-Jul-2012 | Current |
| Praveen Gupta | Director | 13-Dec-1993 | Current |
| Nikunj Gupta | Director | 04-Jul-2012 | Current |
Financial Performance of Denizen Pharmaceuticals India.
Denizen Pharmaceuticals India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.77% decrease. The company also saw a substantial fall in profitability, with a 77.19% decrease in profit. The company's net worth moved up by a moderate rise of 1.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Denizen Pharmaceuticals India?
In 2023, Denizen Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Denizen Pharmaceuticals India?
Unlock and access historical data on people associated with Denizen Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Denizen Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Denizen Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
